Does Harvard Pilgrim Health Care Cover Ozempic?
The verdict
Conditional on most plans
Harvard Pilgrim Health Care covers Ozempic for type 2 diabetes with prior authorization — it does not cover Ozempic for off-label weight-loss use under any plan. As a Point32Health company (alongside Tufts Health Plan) serving New England, Harvard Pilgrim operates in a region that has seen significant GLP-1 weight-loss coverage reductions — but those restrictions target on-label weight-management medications, not Ozempic's T2D indication. Verify tier and PA criteria on Harvard Pilgrim's drug-lookup tool.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Harvard Pilgrim Health Care using your member ID.
Key facts
Ozempic is FDA-approved for type 2 diabetes glycemic control and cardiovascular risk reduction in T2D patients — not for weight loss.
FDA drug labeling (semaglutide injection)
BCBS of Massachusetts ended commercial weight-loss GLP-1 coverage effective January 1, 2026, citing over $300 million in annual GLP-1 spend. Harvard Pilgrim is a separate company.
BCBS of Massachusetts, GLP-1 coverage policy announcement 2025
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027.
CMS, IRA Drug Price Negotiation Program, 2024
Medicare vs. commercial coverage
Whether Harvard Pilgrim Health Care covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Advantage (Harvard Pilgrim / Tufts Health Plan Medicare): Ozempic is covered for type 2 diabetes with prior authorization. PA requires a documented T2D diagnosis and evidence of metformin step-therapy or a documented contraindication. The 2026 Part D out-of-pocket cap of $2,100 limits annual beneficiary spending on covered drugs. Medicare Advantage enrollees cannot use the NovoCare savings card — federal anti-kickback rules exclude Medicare beneficiaries. The IRA Maximum Fair Price for semaglutide (Ozempic/Rybelsus/Wegovy) is $274 per 30-day supply, effective January 1, 2027. Ozempic is not covered for weight loss under Medicare Advantage.
Commercial / Employer
Group & marketplace plans
Commercial/Employer (including national self-funded plans): Harvard Pilgrim covers Ozempic for type 2 diabetes with prior authorization and metformin step-therapy. Formulary tier is not publicly confirmed at the drug level — verify on Harvard Pilgrim's drug-lookup tool. The Harvard Pilgrim/Tufts Health Plan merger under Point32Health may mean shared formulary infrastructure; tier placement should be verified on the specific plan. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25 per fill, max $150 per 28-day supply) — verify at NovoCare.com. Not covered for off-label weight loss. ACA/Individual: covered for T2D with PA; not covered for weight loss. Medicaid (New England Medicaid): Harvard Pilgrim participates in New England Medicaid managed-care markets; covered for type 2 diabetes with prior authorization and nominal Medicaid cost-share. Not covered for off-label weight loss. Medicaid enrollees cannot use the NovoCare savings card.
The 3 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: plan-specific cost-share — not publicly confirmed; verify on Harvard Pilgrim drug-lookup tool or call member services. Medicare Advantage: cost-share depends on plan tier; $2,100 Part D OOP cap applies in 2026; IRA Maximum Fair Price of $274/30-day for semaglutide takes effect January 1, 2027. Medicaid: nominal Medicaid cost-share.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients may pay as little as $25 per fill (max $150 per 28-day supply). Not available to Medicare, Medicaid, VA, DoD, or TRICARE beneficiaries. Verify eligibility at NovoCare.com.
Reduced copay through the assistance program, where eligible.
All figures are estimates — verify exact cost-share with Harvard Pilgrim member services or on the drug-lookup tool. Tier placement and cost-share vary by specific plan and line of business.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up Ozempic on Harvard Pilgrim's drug-lookup tool
Log in to your Harvard Pilgrim member account at harvardpilgrim.org and use the formulary or drug-lookup tool to confirm Ozempic's tier and any prior-authorization or step-therapy requirements. If your plan is a national employer self-funded plan administered by Harvard Pilgrim, verify the specific plan's formulary as it may differ from Harvard Pilgrim's standard commercial formulary.
- 2
Have your prescriber submit the prior-authorization request
Ask your provider to submit a PA request to Harvard Pilgrim documenting: a T2D diagnosis (ICD-10 E11.x), evidence of metformin use or a documented contraindication. The clinical indication must be type 2 diabetes — not weight management. Your prescriber can access Harvard Pilgrim's PA submission portal through the Point32Health provider resources.
- 3
Clarify your plan's relationship to Tufts Health Plan and check 2027 IRA pricing
If your coverage is through a Tufts Health Plan Medicare product (which is now part of Point32Health alongside Harvard Pilgrim), verify formulary details on the Tufts Health Plan side. For Medicare Advantage enrollees, note the IRA Maximum Fair Price of $274/30-day for semaglutide takes effect January 1, 2027. Commercial T2D patients should check NovoCare $25 savings card eligibility. Call member services for a current cost estimate.
Options if Harvard Pilgrim Health Care won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Rybelsus (oral semaglutide)
Oral semaglutide tablet for type 2 diabetes. Also covered for T2D with PA on most formularies. Subject to the IRA Maximum Fair Price of $274/30-day effective January 1, 2027 for Medicare patients. Verify tier on Harvard Pilgrim drug-lookup.
Jardiance (empagliflozin)
SGLT-2 inhibitor commonly used as step-therapy before GLP-1 approval. Often at a lower cost-share tier than Ozempic on commercial formularies.
Metformin (generic)
First-line oral diabetes medication universally covered at low or no cost. Required as step therapy before Ozempic PA in most Harvard Pilgrim plans.
Compounded semaglutide (weight-loss seekers only)
For New England patients seeking semaglutide for weight management who are denied by Harvard Pilgrim, compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without insurance. See the Curex offer section below for full disclaimers.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Harvard Pilgrim does not cover Ozempic for weight loss under any plan. Ozempic holds FDA approval for type 2 diabetes and cardiovascular risk reduction in T2D patients — not for chronic weight management. No insurer covers Ozempic for off-label weight-loss use. New England's GLP-1 coverage landscape has seen significant reductions for weight-management medications (BCBS of Massachusetts ended commercial weight-loss GLP-1 coverage in January 2026), but those restrictions target on-label weight-management drugs and are at a different company — they do not affect Harvard Pilgrim's T2D coverage for Ozempic.
No. BCBS of Massachusetts and Harvard Pilgrim Health Care are separate companies operating independently in the New England market. BCBS of Massachusetts ended commercial weight-loss GLP-1 coverage effective January 1, 2026, citing over $300 million in annual GLP-1 spend. Harvard Pilgrim is a different insurer — it operates under Point32Health alongside Tufts Health Plan. Harvard Pilgrim's own weight-loss GLP-1 coverage position is not publicly confirmed; verify directly. Ozempic's T2D coverage at Harvard Pilgrim is not affected by what BCBS of Massachusetts does.
Yes, Harvard Pilgrim covers Ozempic for type 2 diabetes with prior authorization across its commercial, ACA, Medicare Advantage, and Medicaid lines. Your prescriber must document a T2D diagnosis and metformin step-therapy or a contraindication. Formulary tier and cost-share are not publicly confirmed at the drug level — verify on Harvard Pilgrim's drug-lookup tool. The merger with Tufts Health Plan under Point32Health may mean some shared formulary infrastructure; your plan type determines which formulary applies.
Commercially insured T2D patients on a Harvard Pilgrim commercial plan may be eligible for the NovoCare Ozempic Savings Card ($25 per fill, max $150 per 28-day supply) — verify eligibility at NovoCare.com. Medicare Advantage and Medicaid enrollees cannot use the savings card; federal anti-kickback rules exclude government program beneficiaries. Eligible commercial T2D patients can use this card to significantly reduce out-of-pocket cost while covered under Harvard Pilgrim.
Harvard Pilgrim Health Care and Tufts Health Plan now operate under Point32Health, which may mean shared formulary infrastructure and PA processes. For Ozempic specifically, verify your coverage on the plan-specific drug-lookup tool: harvardpilgrim.org for Harvard Pilgrim plans, or the Tufts Health Plan portal for Tufts-branded plans. Both plans follow the standard T2D-covered-with-PA pattern for Ozempic. If in doubt, call the member services number on your insurance card.
Related Articles
Does Geisinger Health Plan Cover Mounjaro? 2026 Guide | Curex
Geisinger covers Mounjaro for type 2 diabetes with prior auth — not weight loss. PA Medicaid is diabetes-only after the 2025 weight-loss GLP-1 cut.
Read moreDoes Harvard Pilgrim Health Care Cover Mounjaro? 2026 | Curex
Harvard Pilgrim (Point32Health) covers Mounjaro for type 2 diabetes with PA — not weight loss. MA Medicaid covers diabetes; weight-loss GLP-1s restricted.
Read moreDoes Geisinger Health Plan Cover Ozempic? 2026 Guide | Curex
Geisinger covers Ozempic for T2D with PA — not weight loss. Risant/Kaiser ownership does not import Kaiser SGLT-2 step. Verify on Geisinger drug lookup.
Read moreDoes Health Net Cover Mounjaro? California 2026 | Curex
Health Net (Centene, CA) covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Medi-Cal excludes weight-loss GLP-1s from 1/1/2026.
Read moreDoes Harvard Pilgrim Health Care Cover Wegovy? 2026 | Curex
Harvard Pilgrim covers Wegovy only where your employer opted in. New England GLP-1 market tightening — BCBS-MA exited 2026. Verify on the drug-lookup tool.
Read moreDoes Group Health Cooperative Cover Mounjaro? 2026 | Curex
Group Health Cooperative (GHC, WI) covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Composite; verify on plan formulary.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
Harvard Pilgrim does not cover Ozempic for weight loss — and New England's GLP-1 weight-loss coverage environment is tightening. For New England patients seeking semaglutide for weight management without insurance coverage, Curex offers compounded semaglutide starting at $49/mo with no prior authorization needed. Compounded tirzepatide is also available from $149/mo. Compounded semaglutide is not the same medication as Ozempic or Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Harvard Pilgrim Health Care before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.